Baxter books positive Q3
Baxter International has positive financial results for the third quarter of 2009, which ended Sept. 31.

The Deerfield, Ill.-based company said its net income grew 12 percent to $530 million from $472 million reported in the third quarter of 2008. The third quarter results include after-tax special charges totaling $69 million (primarily for fixed asset write-offs related to the discontinuation of the company’s Solomix drug delivery system in development, and planned retirement costs associated with the Syndeo PCA syringe pump). The company recorded after-tax special charges in the third quarter of 2008 totaling $91 million.

Global sales of $3.1 billion were flat compared to the third quarter last year, Baxter said. Excluding the impact of foreign currency, worldwide sales increased 6 percent. U.S. sales increased 5 percent to $1.3 billion in the third quarter, while international sales declined 4 percent to $1.8 billion. Excluding the impact of foreign currency, Baxter said its international sales grew 7 percent.

Sales for the medication delivery unit were of $1.2 billion, representing an increase of 1 percent, according to the company. Renal sales of $576 million declined 3 percent. Contributing to these results was growth across multiple product categories, including products used in peritoneal dialysis treatment, intravenous therapies, injectable drugs and anesthesia products.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup